Back
Sep 28
Education

EDU 04 - Optimizing Sequencing in Immunotherapy and Radiotherapy for Non-Small Cell Lung Cancer - Clinical and Translational Advances

02:45pm - 04:00pm PT
Immunotherapy
Lung Cancer/Thoracic Malignancies

MODERATOR(S)

Alysa Fairchild, MD - Cross Cancer Institute

Houda Bahig, MD, PhD - Centre Hospitalier de lUniversite de Montreal

session DESCRIPTION

This combined immunotherapy track and lung cancer track submission brings together leading experts to discuss recent, cutting-edge trials and strategies in treating both locally advanced and metastatic non-small cell lung cancer (NSCLC). Dr. Louie will present insights from recent pivotal trials such as PACIFIC, PACIFIC-2, and Checkmate 73L, focusing on integrating immunotherapy with radiotherapy and optimizing sequencing, dose, and timing, while also addressing treatment-related toxicities, patient selection criteria, and the controversies surrounding the optimal sequencing of these therapies. Dr. Iyengar will explore the NRG LU002 trial and other recent studies in the oligometastatic and oligoprogressive spaces, offering insights into how sequencing, dose, and timing impact the effectiveness of radiotherapy and immunotherapy combinations, as well as addressing ongoing debates in this area. Dr. Owen will examine the potential of combining radiotherapy and immunotherapy in early-stage NSCLC, including findings from the recent Keynote-867 trial, while considering neoadjuvant approaches and the controversies regarding their clinical applicability. Dr. Schneiders will dive into the biological mechanisms behind combination immunotherapy, focusing on immune modulation, biomarker development, and advanced genomic and proteomic techniques, along with exploring the controversies in biomarker discovery and their role in personalized medicine. Finally, an interactive Q&A session, moderated by Drs. Fairchild and Bahig, will engage attendees in discussions about these advancements, the impact of sequencing and dosing, and the unresolved controversies shaping the future of radio-immunotherapy for lung cancer.

learning objectives

  1. Describe the impact of recent clinical trial data on the integration of immunotherapy and radiotherapy in NSCLC treatment strategies.
  2. Discuss the latest clinical evidence supporting the use of combination immunotherapy, highlighting its efficacy, timing and sequencing with radiotherapy in various stages of NSCLC.
  3. Analyze emerging biomarkers and basic science mechanisms driving the efficacy of combination therapies, and their implications for personalized treatment approaches in NSCLC.

Credits

AMA PRA Category 1 Credits: 1.25

Presentations